CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
IASLC 17th World Conference on Lung Cancer
Oncology Conference Multimedia
View more videos >>
Dr. Carbone on Effectiveness of Different Lung Cancer Therapies
Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC
Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC
Oncology Conference Articles
Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLC
Immunotherapy is quickly becoming a mainstay in the frontline setting for the treatment of patients with metastatic non–small cell lung cancer.
Nivolumab Shows Promise in Mesothelioma
Treatment with the PD-1 inhibitor nivolumab showed promising results in patients with recurrent malignant pleural mesothelioma.
First Steps Taken Toward Harmonization of PD-L1 Immunohistochemistry Testing in France
Determination of the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.
Durvalumab Provides Durable Response in Heavily Pretreated Metastatic NSCLC
Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Atezolizumab Improves Survival in Second-Line NSCLC
Treatment with the PD-L1 inhibitor atezolizumab significantly improved overall survival compared to standard chemotherapy in patients with non–small lung cancer who progressed on platinum-based chemotherapy.
Frontline Pembrolizumab Shows Superior Health-Related QoL in NSCLC
Patients with non–small cell lung cancer treated in the pembrolizumab arm of the KEYNOTE-024 trial experienced improved quality of life compared with patients who were treated with standard chemotherapy.
Osimertinib Beats Chemo in Second-Line T790M-Mutant NSCLC
Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with
T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.
Frontline Ceritinib Improves PFS Over Platinum-Based Chemo in ALK+ NSCLC
Frontline treatment with ceritinib (Zykadia) improved progression-free survival over standard chemotherapy in patients with ALK-rearranged non–small cell lung cancer.
Icotinib Improves Intracranial PFS in EGFR-Mutant NSCLC and Brain Mets
Treatment with icotinib more than doubled intracranial progression-free survival compared with whole brain irradiation combined with standard chemotherapy.
Improved PFS, ORR With Frontline Nivolumab and Nivolumab/Ipilimumab Combo in NSCLC
Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.
Early Results Positive for First-Line Avelumab in NSCLC
Treatment with first-line avelumab yielded promising clinical benefit and durable antitumor activity in patients with advanced non–small cell lung cancer.
Prognostic Factors Plus PD-L1 Expression May Be Linked With Early Survival Risk for Nivolumab in NSCLC
While treatment with nivolumab (Opdivo) significantly improved overall survival over docetaxel in patients with advanced non–small cell lung cancer in the CheckMate-057 trial, an analysis of deaths occurring within 3 months of initiation of therapy showed numerically more deaths in the nivolumab arm.
Expert Highlights Importance of Novel Findings With Tobacco Cessation Practices
Douglas Arenberg, MD, discusses preliminary findings of a screening study, and the critical importance of maintaining quality tobacco cessation practices in healthcare clinics.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
Hereditary Prostate Cancer—What Urologists Should Know
FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC
Targeting BCL-2 in Hematologic Malignancies
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.